Controversial New Alzheimer’s Drug, Aducanumab, Now FDA Approved
The latest drug for treating Alzheimer’s, Aducanumab (also known by the brand name Aduhelm), has recently been granted accelerated approval from the FDA. Alzheimer’s is a debilitating disease that affects 6.2 million Americans and currently has only had therapies that address the symptoms of Alzheimer’s.
Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research states that this drug “is the first therapy to target and affect the underlying disease process of Alzheimer’s,” in regards to the type of treatment Aducanumab is bringing forth. Aducanumab is also the first drug introduced to treat Alzheimer’s Disease since 2003.
Other drugs on the market for Alzheimer’s disease are known to treat and relive symptoms of this condition, however, the trials for Aducanumab have shown that it slows the progression of amyloid beta plaque which is associated with Alzheimer’s in patients during the early stages of the disease. Research found that those receiving the drug during the double-blind, randomized, placebo-controlled trials had a reduction in the plaques while those who did not receive the drug had no plaque reduction.
The controversy behind this drugs approval is within the findings of this study. While it showed a slowing of progression, there was no clear depiction of a lessening of symptoms for Alzheimer’s disease if they took the drug and if there were, the benefit was small. Because of this, the FDA has asked the manufacturer, Biogen, to begin another trial to verify that this therapy is actually effective. Failure to provide proof will result in a revocation of FDA approval.
Side effects of this drug include cerebral edema (swelling of the brain), bleeding from the brain, amyloid-related imaging abnormalities, angioedema (swelling beneath the skin) and urticaria (a hive-like reaction). Administration of the drug is an intravenous infusion for an hour every 4 weeks.
Experts are saying that this drug is only a facet of the entirety of Alzheimer’s and its treatment. Early diagnosis, access to treatment, care management, and care planning are a part of the components associated with treating this disease.
5. Keep baby formula and sterile baby bottles on hand in the case of infection.
We are now offering WALK-IN Vaccines
Monday — Wednesday from 11:00 AM to 5:00 PM for everyone with or without insurance.
To qualify, you must either live, work or go to school in New York. Please bring your ID and insurance card (if you have insurance).
About Us
Here at HealthNeed Medical Urgent Care, our main goal is to provide an easy and friendly walk-in experience that will have you face to face with one of our many medical specialists within minutes of checking in and without an appointment. Our team of medical experts offers treatments anywhere from bandaging small scrapes and cuts to IVs. Come check out our offices that are open 365 days a year. We provide pediatric as well as senior medical care, with most health insurances accepted.
Queens Crossing
38–21 Main St, Suite 1A
Flushing, NY 11354
Wheelchair Accessible Entrance:
136–17 39th Ave, Suite 1A
Flushing, NY 11354
Phone: (718) 888–1808
Terms of Use and Disclaimer — The information contained in this document has been culled from online resources and government agencies and is for general informational purposes only. The information is provided in good faith to support the community and our friends impacted by the COVID-19 pandemic. We makes no representation or warranty of any kind, express or implied, regarding the accuracy or completeness of the information contained herein. Your use of this document and your reliance on the information contained herein is solely at your own risk. All liability with respect to any reader, user or browser’s reliance on this document and/or actions taken or not taken based on the contents of this document is hereby expressly disclaimed.
References:
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
